Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Advanced Purchases For COVID Drugs A Model Post-Pandemic? Not Likely, Manufacturers Warn

Executive Summary

Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.

You may also be interested in...



ICER Extends Influence Among US Insurers With AHIP Subscription Deal

AHIP arrangement is a big win for ICER and will facilitate access to the organization’s cloud-based cost effectiveness review platform for a broad range of payers, particularly small and mid-size companies that may not have the resources to subscribe to the service on their own.

Xtandi March-In Fight Extended to Paxlovid, Insulin, HIV, Asthma And Hepatitis C Drugs

In drug pricing move, Public Citizen and others petition HHS Secretary Becerra to use government authorities to get generic versions of six drugs on the market before patent expiration.

COVID Funding: White House Pleads For Emergency Extension As ‘Runway’ To Commercial Market

Biden administration warns that additional oral antivirals may not be purchased if Congress does not provide $22.5bn emergency funding for COVID response, imperiling the new Test to Treat initiative and other programs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS146045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel